Biosimilar of Remicade Holds Up at 2 Years

29-10-2013 MedPage TodayComments (0)


A monoclonal antibody that's "biosimilar" to infliximab (Remicade) in rheumatoid arthritis showed safety and efficacy profiles that were comparable with the now off-patent original biologic, according to studies presented here. After 2 ...

Read more on MedPage Today

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top